<DOC>
	<DOC>NCT03052751</DOC>
	<brief_summary>The purpose of the study is to evaluate the clinical efficacy of UCB7665 as an chronic-intermittent treatment in subjects with generalized myasthenia gravis (MG) who are classified as moderate to severe.</brief_summary>
	<brief_title>Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis.</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>Subject has a welldocumented diagnosis of myasthenia gravis (MG) at Visit 1 (Screening), based on subject history and supported by previous evaluations Subject would currently be considered for treatment with immunological therapy such as intravenous immunoglobulin/plasma exchange (IVIG/PLEX) by the investigator Subject has documented evidence in his/her medical history or at Screening of detectable autoantibodies (antiacetylcholine receptor+ve (AntiAChR+ve) or antimuscle specific kinase+ve (AntiMuSK+ve) Female subjects must either be: postmenopausal, permanently sterilized or if childbearing potential applicable will use a highly effective method of birth control Male subjects must be willing to use a method of contraception Subject has previously received treatment in this study or subject has previously been exposed to UCB7665 Subject has participated in another study of an investigational medicinal product (IMP;or a medical device) within the previous 30 days of Screening or is currently participating in another study of an investigational medicinal product (IMP; or a medical device) Subject has a known hypersensitivity to any components of the IMP Subject has a history of hyperprolinemia, since Lproline is a constituent of the UCB7665 IMP Subjects with MG only affecting the ocular muscles Subjects with severe weakness affecting oropharyngeal or respiratory muscles, or who have myasthenic crisis at Screening or impending crisis Subject has quantitative myasthenia gravis (QMG) score of &lt;11 at Baseline Subject has a serum total immunoglobulin G (IgG) level &lt;= 6g/L at Screening Absolute neutrophil count &lt;1500 cells/mm^3 Subject has any medical condition (acute or chronic illness) or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study Subject has any laboratory abnormality that, in the opinion of the investigator, is clinically significant, has not resolved at randomization, and could jeopardize or would compromise the subject's ability to participate in this study Subject has received a live vaccination within 8 weeks prior to the Baseline Visit; or intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of IMP Subject has received any experimental biological agent within or outside of a clinical study in the past 3 months or within 5 halflives prior to Baseline (whichever is longer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>UCB7665</keyword>
	<keyword>Myasthenia Gravis</keyword>
</DOC>